Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Recombinant expression and characterization of Lucilia cuprina CYP6G3: Activity and binding properties toward multiple pesticides.

Traylor MJ, Baek JM, Richards KE, Fusetto R, Huang W, Josh P, Chen Z, Bollapragada P, O'Hair RAJ, Batterham P, Gillam EMJ.

Insect Biochem Mol Biol. 2017 Nov;90:14-22. doi: 10.1016/j.ibmb.2017.09.004. Epub 2017 Sep 14.

PMID:
28918158
2.

Determinants of thermostability in the cytochrome P450 fold.

Harris KL, Thomson RES, Strohmaier SJ, Gumulya Y, Gillam EMJ.

Biochim Biophys Acta Proteins Proteom. 2018 Jan;1866(1):97-115. doi: 10.1016/j.bbapap.2017.08.003. Epub 2017 Aug 17. Review.

PMID:
28822812
3.

Exploring the past and the future of protein evolution with ancestral sequence reconstruction: the 'retro' approach to protein engineering.

Gumulya Y, Gillam EM.

Biochem J. 2017 Jan 1;474(1):1-19. doi: 10.1042/BCJ20160507. Review.

PMID:
28008088
4.

Identification, Synthesis, and Biological Evaluation of the Major Human Metabolite of NLRP3 Inflammasome Inhibitor MCC950.

Salla M, Butler MS, Pelingon R, Kaeslin G, Croker DE, Reid JC, Baek JM, Bernhardt PV, Gillam EM, Cooper MA, Robertson AA.

ACS Med Chem Lett. 2016 Sep 27;7(12):1034-1038. eCollection 2016 Dec 8.

5.

Prospects for Applying Synthetic Biology to Toxicology: Future Opportunities and Current Limitations for the Repurposing of Cytochrome P450 Systems.

Behrendorff JB, Gillam EM.

Chem Res Toxicol. 2017 Jan 17;30(1):453-468. doi: 10.1021/acs.chemrestox.6b00396. Epub 2016 Dec 13. Review.

PMID:
27957859
6.

Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.

Toselli F, Dodd PR, Gillam EM.

Drug Metab Rev. 2016 Aug;48(3):379-404. doi: 10.1080/03602532.2016.1221960. Review.

PMID:
27498925
7.

In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.

Bendikov MY, Miners JO, Simpson BS, Elliot DJ, Semple SJ, Claudie DJ, McKinnon RA, Gillam EMJ, Sykes MJ.

Xenobiotica. 2017 Jun;47(6):461-469. doi: 10.1080/00498254.2016.1203041. Epub 2016 Jul 14.

PMID:
27412850
8.

ReX: A suite of computational tools for the design, visualization, and analysis of chimeric protein libraries.

Huang W, Johnston WA, Boden M, Gillam EM.

Biotechniques. 2016 Feb 1;60(2):91-4. doi: 10.2144/000114381. eCollection 2016 Feb.

9.

Gene expression profiling of cytochromes P450, ABC transporters and their principal transcription factors in the amygdala and prefrontal cortex of alcoholics, smokers and drug-free controls by qRT-PCR.

Toselli F, de Waziers I, Dutheil M, Vincent M, Wilce PA, Dodd PR, Beaune P, Loriot MA, Gillam EM.

Xenobiotica. 2015;45(12):1129-37. doi: 10.3109/00498254.2015.1040102. Epub 2015 Jun 22.

PMID:
26095139
10.

Expression of CYP2E1 and CYP2U1 proteins in amygdala and prefrontal cortex: influence of alcoholism and smoking.

Toselli F, Booth Depaz IM, Worrall S, Etheridge N, Dodd PR, Wilce PA, Gillam EM.

Alcohol Clin Exp Res. 2015 May;39(5):790-7. doi: 10.1111/acer.12697.

PMID:
25872594
11.

Directed evolution of cytochrome P450 enzymes for biocatalysis: exploiting the catalytic versatility of enzymes with relaxed substrate specificity.

Behrendorff JB, Huang W, Gillam EM.

Biochem J. 2015 Apr 1;467(1):1-15. doi: 10.1042/BJ20141493. Review.

PMID:
25793416
12.

Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain.

Booth Depaz IM, Toselli F, Wilce PA, Gillam EM.

Drug Metab Dispos. 2015 Mar;43(3):353-7. doi: 10.1124/dmd.114.061242. Epub 2014 Dec 11.

13.

Computational tools for directed evolution: a comparison of prospective and retrospective strategies.

Zaugg J, Gumulya Y, Gillam EM, Bodén M.

Methods Mol Biol. 2014;1179:315-33. doi: 10.1007/978-1-4939-1053-3_21. Review.

PMID:
25055787
14.

Restriction enzyme-mediated DNA family shuffling.

Behrendorff JB, Johnston WA, Gillam EM.

Methods Mol Biol. 2014;1179:175-87. doi: 10.1007/978-1-4939-1053-3_12.

PMID:
25055778
15.

The evolution of cytochrome P450 enzymes as biocatalysts in drug discovery and development.

Gillam EM, Hayes MA.

Curr Top Med Chem. 2013;13(18):2254-80. Review.

PMID:
24047135
16.

Differential expression of human cytochrome P450 enzymes from the CYP3A subfamily in the brains of alcoholic subjects and drug-free controls.

Booth Depaz IM, Toselli F, Wilce PA, Gillam EM.

Drug Metab Dispos. 2013 Jun;41(6):1187-94. doi: 10.1124/dmd.113.051359. Epub 2013 Mar 14.

17.

Measurement of P450 difference spectra using intact cells.

Johnston WA, Gillam EM.

Methods Mol Biol. 2013;987:189-204. doi: 10.1007/978-1-62703-321-3_17.

PMID:
23475679
18.

DNA shuffling of cytochrome P450 enzymes.

Behrendorff JB, Johnston WA, Gillam EM.

Methods Mol Biol. 2013;987:177-88. doi: 10.1007/978-1-62703-321-3_16.

PMID:
23475678
19.

Soluble and membrane-bound Drosophila melanogaster CYP6G1 expressed in Escherichia coli: purification, activity, and binding properties toward multiple pesticides.

Cheesman MJ, Traylor MJ, Hilton ME, Richards KE, Taylor MC, Daborn PJ, Russell RJ, Gillam EM, Oakeshott JG.

Insect Biochem Mol Biol. 2013 May;43(5):455-65. doi: 10.1016/j.ibmb.2013.02.003. Epub 2013 Mar 5.

PMID:
23470655
20.

Directed evolution reveals requisite sequence elements in the functional expression of P450 2F1 in Escherichia coli.

Behrendorff JB, Moore CD, Kim KH, Kim DH, Smith CA, Johnston WA, Yun CH, Yost GS, Gillam EM.

Chem Res Toxicol. 2012 Sep 17;25(9):1964-74. doi: 10.1021/tx300281g. Epub 2012 Aug 29.

21.

Cytochrome P450 is present in both ferrous and ferric forms in the resting state within intact Escherichia coli and hepatocytes.

Johnston WA, Hunter DJ, Noble CJ, Hanson GR, Stok JE, Hayes MA, De Voss JJ, Gillam EM.

J Biol Chem. 2011 Nov 25;286(47):40750-9. doi: 10.1074/jbc.M111.300871. Epub 2011 Oct 5.

22.

Facile production of minor metabolites for drug development using a CYP3A shuffled library.

Hunter DJ, Behrendorff JB, Johnston WA, Hayes PY, Huang W, Bonn B, Hayes MA, De Voss JJ, Gillam EM.

Metab Eng. 2011 Nov;13(6):682-93. doi: 10.1016/j.ymben.2011.09.001. Epub 2011 Sep 22.

PMID:
21963485
23.

The concept lens diagram: a new mechanism for presenting biochemistry content in terms of "big ideas".

Rowland SL, Smith CA, Gillam EM, Wright T.

Biochem Mol Biol Educ. 2011 Jul;39(4):267-79. doi: 10.1002/bmb.20517.

24.

Metabolism of the major Echinacea alkylamide N-isobutyldodeca-2E,4E,8Z,10Z-tetraenamide by human recombinant cytochrome P450 enzymes and human liver microsomes.

Toselli F, Matthias A, Bone KM, Gillam EM, Lehmann RP.

Phytother Res. 2010 Aug;24(8):1195-201. doi: 10.1002/ptr.3111.

PMID:
20135639
25.

Membrane integration of recombinant human P450 forms.

Shukla A, Huang W, Depaz IM, Gillam EM.

Xenobiotica. 2009 Jul;39(7):495-507. doi: 10.1080/00498250902934884.

PMID:
19534586
26.

Echinacea metabolism and drug interactions: the case for standardization of a complementary medicine.

Toselli F, Matthias A, Gillam EM.

Life Sci. 2009 Jul 17;85(3-4):97-106. doi: 10.1016/j.lfs.2009.04.023. Epub 2009 May 8. Review.

PMID:
19427870
27.

In silico characterization of protein chimeras: relating sequence and function within the same fold.

Buske FA, Their R, Gillam EM, Bodén M.

Proteins. 2009 Oct;77(1):111-20. doi: 10.1002/prot.22422.

PMID:
19415757
28.

Re-engineering of CYP2C9 to probe acid-base substrate selectivity.

Tai G, Dickmann LJ, Matovic N, DeVoss JJ, Gillam EM, Rettie AE.

Drug Metab Dispos. 2008 Oct;36(10):1992-7. doi: 10.1124/dmd.108.022186. Epub 2008 Jul 7.

29.

A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.

Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF.

Pharmacogenet Genomics. 2008 Jan;18(1):67-75. doi: 10.1097/FPC.0b013e3282f3606e.

30.

Quantitative whole-cell cytochrome P450 measurement suitable for high-throughput application.

Johnston WA, Huang W, De Voss JJ, Hayes MA, Gillam EM.

J Biomol Screen. 2008 Feb;13(2):135-41. doi: 10.1177/1087057107312780. Epub 2008 Jan 23.

PMID:
18216397
31.

Engineering cytochrome p450 enzymes.

Gillam EM.

Chem Res Toxicol. 2008 Jan;21(1):220-31. Epub 2007 Dec 8. Review.

PMID:
18067267
32.

A shuffled CYP2C library with a high degree of structural integrity and functional versatility.

Huang W, Johnston WA, Hayes MA, De Voss JJ, Gillam EM.

Arch Biochem Biophys. 2007 Nov 15;467(2):193-205. Epub 2007 Aug 30.

PMID:
17904094
33.

A shuffled CYP1A library shows both structural integrity and functional diversity.

Johnston WA, Huang W, De Voss JJ, Hayes MA, Gillam EM.

Drug Metab Dispos. 2007 Dec;35(12):2177-85. Epub 2007 Sep 6.

34.

Extending the capabilities of nature's most versatile catalysts: directed evolution of mammalian xenobiotic-metabolizing P450s.

Gillam EM.

Arch Biochem Biophys. 2007 Aug 15;464(2):176-86. Epub 2007 May 15. Review.

PMID:
17537393
35.

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO.

Br J Clin Pharmacol. 2007 Oct;64(4):450-7. Epub 2007 May 22.

36.

Extending the diversity of cytochrome P450 enzymes by DNA family shuffling.

Rosic NN, Huang W, Johnston WA, DeVoss JJ, Gillam EM.

Gene. 2007 Jun 15;395(1-2):40-8. Epub 2007 Feb 20.

PMID:
17400405
37.

Formation of the indigo precursor indican in genetically engineered tobacco plants and cell cultures.

Warzecha H, Frank A, Peer M, Gillam EM, Guengerich FP, Unger M.

Plant Biotechnol J. 2007 Jan;5(1):185-91.

38.

STAR: predicting recombination sites from amino acid sequence.

Bauer DC, Bodén M, Thier R, Gillam EM.

BMC Bioinformatics. 2006 Oct 8;7:437.

39.

Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.

Avent KM, DeVoss JJ, Gillam EM.

Chem Res Toxicol. 2006 Jul;19(7):914-20.

PMID:
16841959
40.

An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO.

Br J Clin Pharmacol. 2006 May;61(5):570-84.

41.

Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.

Notley LM, Crewe KH, Taylor PJ, Lennard MS, Gillam EM.

Chem Res Toxicol. 2005 Oct;18(10):1611-8.

PMID:
16533026
42.

P450 2C18 catalyzes the metabolic bioactivation of phenytoin.

Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM.

Chem Res Toxicol. 2005 Dec;18(12):1868-75.

PMID:
16359177
43.

Functional characterisation of an engineered multidomain human P450 2E1 by molecular Lego.

Fairhead M, Giannini S, Gillam EM, Gilardi G.

J Biol Inorg Chem. 2005 Dec;10(8):842-53. Epub 2005 Nov 9.

PMID:
16283395
44.

Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes.

Matthias A, Gillam EM, Penman KG, Matovic NJ, Bone KM, De Voss JJ, Lehmann RP.

Chem Biol Interact. 2005 Jun 30;155(1-2):62-70.

PMID:
15885678
45.

Modified nicotine metabolism in transgenic tobacco plants expressing the human cytochrome P450 2A6 cDNA.

Dueckershoff K, Unger M, Frank A, Gillam EM, Guengerich FP, Warzecha H.

FEBS Lett. 2005 Apr 25;579(11):2480-4.

47.

Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9).

Davies C, Witham K, Scott JR, Pearson A, DeVoss JJ, Graham SE, Gillam EM.

Drug Metab Dispos. 2004 Apr;32(4):431-6.

48.

Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group.

Cheesman MJ, Baer BR, Zheng YM, Gillam EM, Rettie AE.

Arch Biochem Biophys. 2003 Aug 1;416(1):17-24.

PMID:
12859977
49.

Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism.

Lewis DF, Gillam EM, Everett SA, Shimada T.

Chem Biol Interact. 2003 Jun 15;145(3):281-95.

PMID:
12732455
50.

Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies.

Peter Guengerich F, Chun YJ, Kim D, Gillam EM, Shimada T.

Mutat Res. 2003 Feb-Mar;523-524:173-82. Review.

PMID:
12628515

Supplemental Content

Loading ...
Support Center